Janney Montgomery Scott Upgrades Clovis Oncology (CLVS) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Clovis Oncology (CLVS) PT Raised to $111 at JPMorgan
June 20, 2017 8:07 AM EDTJPMorgan analyst Cory Kasimov raised his price target on Clovis Oncology (NASDAQ: CLVS) to $111.00 (from $72.00) while maintaining a Overweight rating.
Kasimov said the ARIEL 3 topline data represents more or less a best case scenario for CLVS. He thinks ARIEL 3... More
Clovis Oncology (CLVS) PT Raised to $107 at Credit Suisse; Major De-Risking Event
June 20, 2017 6:59 AM EDTCredit Suisse raised its price target on Clovis Oncology (NASDAQ: CLVS) to $107.00 (from $88.00) while maintaining an Outperform rating on increased probability of success in 1L and 2L ovarian after ARIEL3 success
Alethia Young viewed the data today as a major de-risking... More
Clovis Oncology (CLVS) PT Raised to $90 at Goldman Sachs, Raises Estimates, Possible Takeout Candidate
June 20, 2017 6:32 AM EDTGoldman Sachs raised its price target on Clovis Oncology (NASDAQ: CLVS) to $90.00 (from $67.00) while maintaining a Neutral rating.
Analyst Dr. Terrence Flynn updates Rubraca estimates and now models Rubraca WW peak sales of $1.8 billion compared with the prior estimate of $1.2... More
Clovis Oncology (CLVS) PT Raised to $114 at Leerink Partners, Prime takeout Candidate
June 19, 2017 2:49 PM EDTLeerink Partners raised its price target on Clovis Oncology (NASDAQ: CLVS) to $114.00 (from $85.00) while maintaining a Outperform rating.
Te analyst says the new price target is reflective of three key points:
our previously outlined best-case scenario for Rubraca,incorporation of a low... More